Using its patented innovative technology, BioNet is leading the development and manufacturing of next-generation pertussis vaccines.
BioNet’s recombinant acellular pertussis vaccine is unique in that it contains a genetically inactivated pertussis toxin (PTgen), a component found in all acellular pertussis vaccines.
PTgen has been extensively evaluated in clinical trials involving children and adults.
BioNet’s recombinant pertussis vaccine is licensed in Asia as Pertagen®, and applications for licensure under different names have been submitted in other regions.
We lead in the development of recombinant acellular pertussis vaccines using PTgen – a genetically detoxified pertussis toxin that preserves the native protein structure for stronger, longer-lasting immunity.
Recombinant Pertussis Vaccines
– Recombinant aP: Stand-alone booster (licensed)
– Recombinant TdaP: Combination Td-pertussis booster (licensed)
– Recombinant Tdap: Reduced-dose combination booster (licensed)
– Recombinant DTaP: Pediatric combination vaccine (in development)
It uses PTgen, a genetically detoxified toxin that maintains structural integrity for enhanced immunogenicity compared to chemically detoxified vaccines.
Traditional vaccines use chemicals like formaldehyde for detoxification, which may alter the antigen. PTgen retains its native conformation, triggering a stronger immune response.
Yes. Our vaccines have demonstrated excellent safety across multiple clinical trials and post-marketing surveillance.
Anyone requiring a booster, especially adolescents, adults, pregnant women, and the elderly.
Administering Tdap between weeks 27–36 transfers antibodies to the newborn, offering critical early protection.
Contact us and be part of the journey.
Our Location
Thailand
19 Soi Udomsuk 37, Bangkok 10260, Thailand
France
41 Cours de la Liberté 69003 Lyon Cedex 03, France
Social network